Cargando…

Ebselen, a new candidate therapeutic against SARS-CoV-2

Detalles Bibliográficos
Autores principales:	Haritha, C.V., Sharun, Khan, Jose, Bosco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IJS Publishing Group Ltd. Published by Elsevier Ltd. 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583587/ https://www.ncbi.nlm.nih.gov/pubmed/33120196 http://dx.doi.org/10.1016/j.ijsu.2020.10.018

Ejemplares similares

SARS-CoV-2 in semen: Potential for sexual transmission in COVID-19
por: Sharun, Khan, et al.
Publicado: (2020)

Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19
por: Sharun, Khan, et al.
Publicado: (2020)

Spray-Dried Inhalable Microparticles Combining Remdesivir and Ebselen against SARS-CoV-2 Infection
por: Saha, Tushar, et al.
Publicado: (2023)

Molecular characterization of ebselen binding activity to SARS-CoV-2 main protease
por: Menéndez, Cintia A., et al.
Publicado: (2020)

Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir
por: Chen, Ting, et al.
Publicado: (2021)

Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives
por: Amporndanai, Kangsa, et al.
Publicado: (2021)

SARS, MERS, and COVID-19: What's next?
por: Sharun, Khan
Publicado: (2020)

The Mpro structure-based modifications of ebselen derivatives for improved antiviral activity against SARS-CoV-2 virus
por: Qiao, Zhen, et al.
Publicado: (2021)

Ebsulfur and Ebselen as highly potent scaffolds for the development of potential SARS-CoV-2 antivirals
por: Sun, Le-Yun, et al.
Publicado: (2021)

Correction to “Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir”
por: Chen, Ting, et al.
Publicado: (2021)

Electrochemical Biosensor for the Detection of SARS-CoV-2 Main Protease and Its Inhibitor Ebselen
por: Zhang, Qiongyu, et al.
Publicado: (2022)

Chloroquine drops against SARS-CoV-2 infection
por: Kumar, Jogender, et al.
Publicado: (2022)

Enoxaparin’s potential mechanisms against SARS-CoV-2
por: Afsharirad, Bentelhoda, et al.
Publicado: (2023)

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics
por: Standl, Fabian, et al.
Publicado: (2021)

An action plan for pan-European defence against new SARS-CoV-2 variants
por: Priesemann, Viola, et al.
Publicado: (2021)

Modulation of IRAK enzymes as a therapeutic strategy against SARS-CoV-2 induced cytokine storm
por: Mahmoud, Ismail Sami, et al.
Publicado: (2023)

Fighting the Battle against SARS-CoV-2 as Gastroenterologists in Italy
por: Pagnini, Cristiano, et al.
Publicado: (2020)

Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1
por: van Doremalen, Neeltje, et al.
Publicado: (2020)

BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants
por: Liu, Yang, et al.
Publicado: (2021)

Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies
por: Yamasoba, Daichi, et al.
Publicado: (2022)

Sunitinib reduces the infection of SARS-CoV, MERS-CoV and SARS-CoV-2 partially by inhibiting AP2M1 phosphorylation
por: Wang, Pei-Gang, et al.
Publicado: (2020)

Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection
por: Lin, Qingqing, et al.
Publicado: (2020)

Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
por: Zang, Jinkai, et al.
Publicado: (2020)

Testing for responses to the wrong SARS-CoV-2 antigen?
por: Rosadas, Carolina, et al.
Publicado: (2020)

Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
por: Altarawneh, Heba N., et al.
Publicado: (2022)

Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant
por: Chemaitelly, Hiam, et al.
Publicado: (2021)

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants
por: Pallett, Scott J C, et al.
Publicado: (2022)

Cross-reactive antibody immunity against SARS-CoV-2 in children and adults
por: Fraley, Elizabeth, et al.
Publicado: (2021)

Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2
por: Fang, Zhenhao, et al.
Publicado: (2022)

Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV
por: Zheng, Ming, et al.
Publicado: (2020)

Oral cavity infection by the SARS-CoV-2: emphasizing the essence of masking and peptide therapeutics
por: Ibiang, Glory Omini, et al.
Publicado: (2022)

Structure‐Activity Studies Reveal Scope for Optimisation of Ebselen‐Type Inhibition of SARS‐CoV‐2 Main Protease
por: Thun‐Hohenstein, Siegfried T. D., et al.
Publicado: (2021)

Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2
por: Weglarz-Tomczak, Ewelina, et al.
Publicado: (2021)

Ebselen and Diphenyl Diselenide Inhibit SARS-CoV-2 Replication at Non-Toxic Concentrations to Human Cell Lines
por: Wildner, Guilherme, et al.
Publicado: (2023)

SARS-CoV-2 shedding and infectivity
por: Atkinson, Barry, et al.
Publicado: (2020)

The proximal origin of SARS-CoV-2
por: Andersen, Kristian G., et al.
Publicado: (2020)

SARS-CoV-2 Infection in Children
por: Lu, Xiaoxia, et al.
Publicado: (2020)

SARS-CoV-2 seroprevalence in Spain
por: George, Thukalan Paulose
Publicado: (2020)

SARS CoV2 vaccine and aphasia
por: sookaromdee, Pathum, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v7fv9l02bsskm7vhj96tdol0ll